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Background: Defective interfering (DI) viruses are natural antivirals made by nearly all viruses. They have a highly
deleted genome (thus being non-infectious) and interfere with the replication of genetically related infectious
viruses. We have produced the first potential therapeutic DI virus for the clinic by cloning an influenza A DI
RNA (1/244) which was derived naturally from genome segment 1. This is highly effective in vivo, and has
unexpectedly broad-spectrum activity with two different modes of action: inhibiting influenza A viruses through RNA
interference, and all other (interferon-sensitive) respiratory viruses through stimulating interferon type I.
Results: We have investigated the RNA inhibitory mechanism(s) of DI 1/244 RNA. Ablation of initiation codons does
not diminish interference showing that no protein product is required for protection. Further analysis indicated that 1/244
DI RNA interferes by replacing the cognate full-length segment 1 RNA in progeny virions, while interfering with the
expression of genome segment 1, its cognate RNA, and genome RNAs 2 and 3, but not genome RNA 6, a representative
of the non-polymerase genes.
Conclusions: Our data contradict the dogma that a DI RNA only interferes with expression from its cognate full-length
segment. There is reciprocity as cloned segment 2 and 3 DI RNAs inhibited expression of RNAs from a segment 1 target.
These data demonstrate an unexpected complexity in the mechanism of interference by this cloned therapeutic DI RNA.
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Viral replication frequently generates progeny genomes
that contain extensive deletions [1–4]. This is thought to
be a consequence of the polymerase detaching from the
initial template and reattaching elsewhere on the same
or different template. The truncated genomes are unable
to generate infectious virus particles and are thus func-
tionally defective. During a single infectious cycle a large
number of different defective genomes can be generated,
each lacking a different portion of the genome. Mole-
cules containing the necessary signals will be replicated
and packaged into virus particles. Some, but not all, of
these defective genomes are also capable of interfering
with the growth of the parental virus from which they
were derived and are known as defective-interfering (DI)* Correspondence: a.j.easton@warwick.ac.uk
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(http://creativecommons.org/publicdomain/zegenomes [5]. The ability to interfere with virus multipli-
cation suggests that these DI genomes could act as
antiviral agents in the clinic [6, 7].
The influenza A virus genome comprises 8 segments
of single-stranded negative-sense RNA (vRNA) in the
form of ribonucleoprotein (RNP) complexes, and one
copy of each of these segments is required to make an
infectious virus particle [8–10]. Influenza virus infections
can generate DI RNAs, which can interfere with virus
replication. No copyback or snapback influenza DI
RNAs have been detected, and most influenza DI RNAs
have a major (approximately 80%) internal deletion,
while retaining the cis-acting signals required for replica-
tion and packaging into virus particles [11–13]. DI RNA
is incorporated into a particle but the resulting DI virus
cannot replicate autonomously since it is unable to syn-
thesise the protein(s) normally encoded by the deleted
segment. Replication of a DI virus thus requires comple-
mentation by infectious virus. However, DI RNAs mayle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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role in interference of infectious virus replication [14, 15].
Influenza virus genome replication commences with
synthesis of positive-sense (cRNA) copies of the vRNAs
of the infecting virus, and in turn these are used as tem-
plates for synthesis of new vRNAs [10]. vRNA is also
used as the template for mRNA transcription. Unlike
cRNA synthesis, mRNA synthesis is initiated using a pri-
mer cleaved from the capped 5′ end of host mRNAs
and its synthesis terminates before the end of the tem-
plate vRNA, prior to polyadenylation [16–19]. Thus the
mRNA differs from cRNA in having the primer-derived
5′-extension, being truncated, and being polyadenylated
at the 3′ end. The non-coding termini of each segment
are crucial for RNA synthesis, and contain a conserved,
approximately 12 nucleotide (nt), sequence at the 5′ end
which is almost exactly complemented at the 3′ end [10].
Synthesis of influenza virus RNAs is carried out by a
virus-encoded RNA-dependent RNA polymerase present
within a RNP complex consisting of the vRNA or cRNA
in association with the virus NP protein and the heterotri-
meric virus RNA polymerase comprised of the PB1, PB2
and PA proteins. The latter are encoded by vRNA seg-
ments 2, 1 and 3, respectively. Mutations in PB2 and PA
can decouple transcription (mRNA synthesis) from repli-
cation (vRNA and cRNA synthesis), such that a mutant
polymerase is defective in replication but not in transcrip-
tion or vice versa [20, 21]. Although initiation of mRNA
and cRNA synthesis differ in mechanism, a ‘switch’ direct-
ing the polymerase to synthesise one or the other has not
been clearly demonstrated, and both can be synthesised
from vRNP in a cell-free system [22, 23]. The polymerase
complex binds to conserved sequences at the 5′ and 3′
ends of vRNA and cRNA [24–26]. The termini of cRNA
differ from those of vRNA at several nucleotide positions,
and critical residues of each may interact with distinct re-
gions of the PB1 protein [27, 28]. Synthesis of vRNA and
cRNA can also be affected differentially by mutations in
the NP or NS1 proteins [29–31], or by the presence or ab-
sence of the NS2 protein [32].
Little progress has been made towards understanding the
mechanism of interference by DI viruses. For snapback/
copyback vesicular stomatitis virus (VSV) DI RNAs that have
a high degree of double-strandedness, but not VSV DI RNAs
generated by central deletion, the key factor in interference
seems to be the extent of terminal complementarity of the
DI RNA such that a longer DI RNA with more extensive ter-
minal complementarity out-competes a shorter DI RNA of
the same structure [33–35]. In addition, lack of a transcrip-
tional promoter in snapback/copyback DI RNAs gives them
a replicative advantage over full-length genomic RNA or
centrally deleted DI RNAs that can carryout transcription [3,
13, 36–39]. These properties may explain the observed pre-
ponderance of rhabdovirus copyback/snapback DI RNAs.For DI RNAs generated by a central deletion, as seen in in-
fluenza viruses, it has been suggested that interference with
RNA synthesis involves competition between the DI RNA
and genomic RNA for limiting viral or host factor(s), and/or
the much shorter DI RNA may have a more rapid rate of
synthesis than its cognate genomic RNA giving it a competi-
tive advantage, although there is little experimental evidence
supporting this [3, 13, 36–40].
Most studies of DI influenza virus-mediated interfer-
ence to date have been carried out with naturally occur-
ring preparations, and are compromised by the presence
of mixtures of several different defective RNA sequences
[4, 41]. This problem was solved using reverse genetics
to generate virus stocks containing a molecularly defined
naturally occurring DI RNA. Called 1/244 to denote its
derivation from segment 1 and the number of nucleo-
tides retained at the 3′ end of the positive-sense RNA, it
is propagated and efficiently maintained by infectious
virus often referred to as ‘helper’ virus. When delivered
intranasally as an influenza virus particle, 1/244 DI virus
confers complete protection in mice from a lethal chal-
lenge with several different subtypes of influenza A virus
(homologous protection) and is more effective than osel-
tamivir in ferrets in combatting pandemic influenza A/
California/04/09 [42]. However, the molecular basis of
this homologous protection by 1/244 DI virus is not
known. In addition, 1/244 DI virus also protects from
the genetically heterologous influenza B virus and a
murine pneumovirus in a dose-dependent manner
through its ability to induce the local expression of inter-
feron type I, although induction of interferon is not re-
quired for protection against influenza A virus [43, 44].
Here we show that interference with influenza A virus
mediated by molecularly cloned 1/244 DI RNA does not
require expression of a protein product from the deleted
segment 1 but results from both competition with the
packaging of full-length cognate virion segment 1 RNA,
and by inhibiting the synthesis and/or accumulation of
RNA directed by segment 1 RNA. Unexpectedly 1/244
DI RNA also interfered with the expression of RNAs
from full-length segments 2 and 3, which encode the
other polymerase proteins, but not from full-length seg-
ment 6.
Methods
Plasmids
The plasmids encoding the 8 gene segments of the A/
WSN strain of A/WS/33 (H1N1) and plasmids express-
ing the polymerase proteins and NP [45], and the con-
struct expressing 1/244 DI RNA (1/244), derived from a
naturally occurring DI virus, were as previously described
[46]. 1/244 RNA comprises 395 nt with 151 nt from the
5′ end and 244 nt from the 3′ end of the positive-sense
cognate RNA and was derived naturally from segment 1
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get, segment 1-GFP, expressing the green fluorescent pro-
tein (GFP), was created by amplifying the GFP open
reading frame by PCR from pEGFP-N1 (Clontech) using
primers 5’ATGGTCTCTACTGATGGTGAGCAAGGGC-
GAG and 5’ATGAAGACAATCTCTTACTTG
TACAGCTCGTCCA. The product was inserted between
the BpiI and Eco31I sites of pPolI-220 [47] such that the
GFP ORF is in-frame with the PB2 ORF, giving plasmid
seg 1-GFP which expresses segment 1-GFP RNA (Fig. 1).
The GFP reporter retains the exact 5′ (220 nt) and 3′
(48 nt) terminus of segment 1 and is cognate for 1/244 DI
RNA. A naturally occurring segment 2 DI (2/265; com-
prising 452 nt in total with 265 nt from the 3′ end and
187 nt from the 5′ end of the positive-sense cognate
RNA) was isolated from a DI A/equine/Newmarket/7339/
79 (H3N8) virus preparation (Fig. 1) [48] by RT-PCR amp-
lification, and subsequently cloned into a pPolI-SapITFig. 1 a. Schematic diagram of influenza segment 1244 DI RNA (1/244), segme
RNA expressed from plasmids. The names derive from the 244, 265 and 262 nt
of nucleotides comprising each RNA is shown on the right. The nucleotide pos
this study (positive-sense, 5′ to 3′) are indicated. Solid arrows indicate the prime
dashed arrows indicate primers used for vRNA analyses. For the construction of
indicating the open reading frame, and the predicted protein sequen
domain of PB2 is indicated by the dark grey box, and the 22 residue
grey box. The boxed amino acid sequence downstream from the cen
the PB2 ORF. The three G → C mutations at nucleotide positions 30,
are shown in bold and underlinedexpression vector [49]. A further naturally occurring seg-
ment 3 DI RNA (3/262; comprising 469 nt in total with
262 nt from the 3′ end and 207 nt from 5′ end of the
positive-sense cognate RNA) was isolated from a DI A/
WSN preparation, and was amplified and cloned as above
(Fig. 1). The DI RNAs encoded by the various plasmids re-
tain the exact nucleotide sequences from the termini of
the genome segments of the viruses from which they were
derived and do not contain any mutations in positions
known to have an effect on replication or packaging. Two
sequential steps of site-directed mutagenesis were carried
out to mutate the start codons in the 1/244 DI RNA. A
pair of primers (GTTCTTTTATTCTTTCgATATTGAAT
ATAATTG and CAATTATATTCAATATcGAAAGAAT
AAAAGAAC) was used for site-directed mutagenesis to
convert the first AUG to AUC using a pPolI-244 plasmid
as template and Pfu DNA polymerase (Promega). The
lower case letters indicate the position of the mutations.nt 2265 DI RNA (2/265), segment 3262 DI RNA (3/262), and the Seg 1-GFP
remaining at the 3′ end of the cognate vRNAs respectively.The total number
itions of the breakpoints that result in the deleted genome RNAs used in
rs used in the primer extension assays for cRNA and mRNA analyses and
Seg 1-GFP RNA see Methods. b. Sequence of 1/244 DI RNA in cRNA sense
ce in single letter amino acid code. The 35 residue PB1 binding
mitochondrial interaction domain of PB2 is indicated by the light
tral deletion that gave rise to 1/244 DI RNA do not arise from
60 and 111 used to mutate the in-frame AUG initiation codons
Meng et al. Virology Journal  (2017) 14:138 Page 4 of 16The second round of site-directed mutagenesis used
primers that altered the second and third start codons to
AUC using the construct produced from the first round of
mutagenesis (CTTCTTGATTATGGCcATATGGTCCAC
GGTGGTTTTTGTGAGTATCTCGCGGGTGCGAGAC
TGCGAcATTAGATTTCTTAGT and ACTAAGAAA
TCTAATgTCGCAGTCTCGCACCCGCGAGATACTC
ACAAAAACCACCGTGGACCATATgGCCATAATCA
AGAAG). All constructs were confirmed by sequencing.
Transfection and recovery of infectious virus
Human 293T cells (American Type Culture Collection)
were transfected as previously described. Briefly, for
northern blot analysis, a well of 70% confluent 293T cells
in a 12-well plate was transfected using TransIT LT1
transfection reagent (Mirus) with 8 PolI expression plas-
mids encoding virion sense RNA, and cDNA plasmids for
expression of PB2, PB1, PA and NP proteins, with or with-
out pPolI-244. The transfected cells were then incubated
at 37 °C overnight before co-culture with MDCK cells
(obtained from the American Type Culture Collection) in
a 25 cm2 flask. Total cellular RNA was extracted with
2 ml Trizol reagent per sample (Invitrogen) on days 1, 2
and 3 after co-culture while tissue culture fluid was col-
lected for virus titration and RNA extraction. Virions were
purified by ultracentrifugation. RNA was extracted with
phenol/chloroform, and then ethanol precipitated.
For preparation of virus stocks containing DI 1/244
and 1/244 KO DI RNA, virus in tissue culture fluids
produced by transfection was passaged once in embryo-
nated chicken’s eggs and allantoic fluids were harvested
to produce a stock of virus. The virus produced in em-
bryonated chicken’s eggs is a mixture of 1/244 DI virus
or 1/244 AUG KO DI virus packaged in A/WSN virion
proteins and infectious helper A/WSN strain of A/WS/
33 (H1N1) virus. These were purified by differential cen-
trifugation through sucrose, and resuspended in PBS.
Stocks were standardized according to their haemagglu-
tination titre and stored in liquid nitrogen. The DI virus
stock was UV-irradiated to remove helper virus infectiv-
ity using a short burst (40 s) of UV irradiation at
253.7 nm (0.64 mW/cm2). This is ‘active DI virus’. Lon-
ger UV irradiation (8 min) inactivates the protective ac-
tivity in mice, but does not affect haemagglutinin or
neuraminidase activities, and so controls for any im-
mune system-stimulating or receptor-blocking effects of
1/244 DI virus particles (‘inactivated DI virus’).
Infectivity assay
MDCK cell monolayers in 96-well plates were in-
fected with supernatant containing rescued A/WSN as
described previously [44]. After 1 h for attachment of
virus, the monolayer was washed with PBS, and incubated
in maintenance medium overnight at 33 °C. Cells werethen fixed with 4% (v/v) formaldehyde, washed and
blocked with 5% (w/v) milk powder in PBS. The infected
cells were probed with a monoclonal antibody specific for
the HA of A/WSN in PBS containing 0.1% Tween 20.
After washing, goat anti-mouse IgG–alkaline phosphatase
conjugate (Sigma) in TBS containing 0.1% Tween 20 was
added, and infected cells were detected with nitrotetrazo-
lium blue chloride/BCIP (Sigma) in Tris-buffered magne-
sium chloride and sodium chloride (0.1 M, pH 9.5). The
infectivity titre was determined by counting at least 50
positively stained cells (foci) at an appropriate dilution in
each of the triplicate wells. The mean number of counts
was determined to give a titre in focus-forming units
(f.f.u.) ml−1.
Protection of mice from influenza with DI virus
To assess the degree of in vivo protection afforded by DI
virus, groups of 5 C3H/He-mg mice were each inoculated
intranasally under light ether anaesthesia with A/WSN
alone (10 LD50 or 1000 f.f.u.), active DI virus alone, a mix-
ture of A/WSN + active DI virus, or A/WSN + inactivated
DI virus. The amounts of DI 1/244 used was the same as
used in previous studies of protection from disease and
mice were subsequently monitored for clinical disease ac-
cording to our standard protocol [43, 44]. The severity of
disease was scored using the standard scoring system with
a score of 1 indicating a healthy animal and a score of 5
indicating death with a range of severity of cinical signs
for intervening scores as described previously [43, 44].
Animals were assessed daily and data are expressed as the
mean score for each group. Surviving mice were chal-
lenged 3 weeks after infection with a high dose of A/WSN
(10,000 LD50) to determine their immune status. All work
with animals was governed by a licence approved by the
UK Home Office and complied with national regulations.
Animal work was approved by the University of Warwick
Animal Welfare and Ethical Review Board as required by
the Animals (Scientific Procedures) Act (1986) governing
animal experimentation in the UK. Animals culled for hu-
mane reasons were subjected to an approved procedure to
minimise suffering.
RNA extraction and primer extension
For primer extensions, each well of a 6 well plate con-
taining 70% confluent 293T cells was transfected with
1 μg each of the PB2, PB1, PA and NP cDNA expression
plasmids plus various amounts of either a DI plasmid,
pPolI-PB2, or pPolI-NA together with 1 μg of target
plasmid. Cells were incubated at 37 °C and total cellular
RNA was extracted from cells with Trizol at 48 h post-
transfection.
Primer extension analysis was carried out as previously
described [50], using primer mixes in order to detect
vRNA, cRNA, mRNA and 5S rRNA simultaneously from
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[32P]5′-end labelled primers and dNTP in a total volume
of 13 μl. The mixture was heated at 65 °C for 5 min and
placed on ice for 1 min. 2X first Strand Buffer, 20 mM
DTT, and 100 U SuperScript III reverse transcriptase
(Invitrogen) were added and further incubated at 55 °C
for 1 h. The reaction was terminated by heating at 95 °C
for 5 min with gel loading dye II (Ambion). The tran-
scription products were resolved on a 6% (w/v) poly-
acrylamide gel containing 7 M urea in TBE buffer and
detected by phosphor imaging. The primers used, and
the expected product sizes, are shown in Table 1 and the
positions of these on the various target RNAs are dem-
onstrated in Fig. 1a.
Northern blotting
Ten μg of total cellular RNA or 50% of the yield of puri-
fied virion RNA from each sample was analysed by
glyoxal-agarose gel electrophoresis. Poly A-containing
mRNA was selected using a GenElute Direct mRNA
preparation kit (Sigma) according to the manufacturer’s
instructions. Non-polyadenylated RNA that did not bind
to the column during mRNA preparation, and therefore
contained the viral cRNA, was retained for further study.
The RNA was transferred onto Hybond-N membrane (GE
Healthcare) overnight using 20× SSC. The membrane was
then baked at 80 °C for 2 h and hybridized with digoxi-
genin (DIG)-labelled probes overnight. The full-length
positive-sense DIG-labelled segment 1, segment 2 and
segment 7 probes were transcribed in vitro in the presence
of DIG-UTP (Roche) from PCR products containing a T7
promoter. The Roche system with a digoxigenin-specific
FAb antibody fragment conjugated to alkaline phosphatase
and the chemiluminescent CSPD substrate was used for
detection. Blots were exposed to Fuji X-ray film until theTable 1 Sequences of the primers used in this study. The primers co
both A/PR8 and A/WSN-derived RNAs. Influenza virus mRNAs utilise
the mRNA fragments reflect this heterogeneity
Target RNA Primer specificity Prime
Seg 1-GFP c/mRNA GGAC
vRNA AGAT
DI 1/244 c/mRNA ATAT
vRNA GGAG
Segment 2 (PB1) c/mRNA* TCCA
vRNA* TGAT
Segment 3 (PA) c/mRNA* TGAG
vRNA* TTCT
Segment 6 (NA) c/mRNA* TCCA
vRNA* TGGA
5S rRNA* TCCC
* indicates primers taken from [50]desired density was achieved and bands were quantified by
densitometry using ImageJ (NIH).
Quantitation of GFP-expressing cells
Human 293T cells were transfected with the segment 1-
GFP RNA expressing plasmid, plasmids expressing PB1,
PB2, PA and NP proteins, and increasing amounts of an
additional PolI plasmid expressing a DI RNA (1/244, 2/265
and 3/262) or a full-length RNA (segment 1, 4 or 6). At 2
days post-transfection, the cultures were examined for GFP
expression. Each dataset was replicated several times and
all data were included in the calculations. Digital images of
the cell monolayers were taken by phase-contrast and
epifluorescence microscopy. Five field fluorescence images
were randomly selected and analysed for the proportion of
the visualised area expressing GFP using the HCImage
software (Hamamatsu). The visualisation detects cells ex-
pressing a range of GFP levels to include those that may
have been transfected with different levels of the reporter
plasmids. A mean was calculated to give the percentage of
the GFP positive area per monolayer.
Results
1/244 DI RNA directs synthesis of a small mRNA in the
presence of infectious helper virus
It has been shown that a truncated form of the flu A
PB2 protein is capable of inducing type I interferon and
an antiviral state [15]. DI 1/244 RNA contains the 3′ ter-
minal 244 nt of the segment 1 vRNA that may direct
mRNA synthesis and would consequently have the po-
tential to encode a truncated protein containing the
amino terminus of PB2 (Fig. 1a, b). We therefore investi-
gated if the synthesis of the potential truncated protein
from 1/244 DI RNA had a role in interference or protection
against influenza in vivo. First, we determined if 1/244 DIntaining mixed nucleotides were designed for detection of
primers that are 10–13 nt in length and the predicted sizes of
r sequence Expected product Size/s (nt)
ACGCTGAACTTGTGG 142/152–5
AAGAGGATAATGGAAATG 242
GGTCCACKGTGGTTTTTG 110/120–3
AAGACTGAGGGGATTC 252
TGGTGTATCCTGTTCC 146/156–9
TTCGAATCTGGAAGGA 134
TGCATATTGCTGCAAAT 146/156–9
TATCGTTCAGGCTCTT 213
GTATGGTTTTGAYTTCCR 160/170–3
CTAGTGSGAGCATSAT 130
AGGCGGTCTCCCATCC 100
Meng et al. Virology Journal  (2017) 14:138 Page 6 of 16RNA could direct the synthesis of mRNA by analysing the
viral RNAs present in cells infected with 1/244 DI virus and
infectious helper virus. As with all DI viruses 1/244 DI virus
is replication incompetent, in this case due to the lack of a
functional genome segment 1. To study the viral RNAs
synthesised from 1/244 we therefore co-infected cells with
1/244 virus and infectious A/WSN (H1/N1) as helper virus
to provide the segment 1 encoded PB2 protein needed to
generate 1/244 RNAs. Both viruses were generated entirely
from molecular clones by reverse genetics as described pre-
viously [51] to avoid the presence of other DI RNAs.
Northern blot analysis using a segment 1 specific probe de-
tected two polyadenylated virus mRNAs, of approximately
2.3 and 0.5 kb, in infected cells (Fig. 2a). These sizes are
consistent with mRNAs predicted to be derived from the
full-length genome segment 1 provided by the helper virus
and by 1/244 DI RNA, respectively. The positive-sense
RNA seen in the non-polyadenylated RNA fraction is
cRNA and, as expected, was slightly smaller than the 1/244
DI-derived mRNA. These data indicate that the 1/244 DIFig. 2 Detection of RNAs synthesised by 1/244 DI RNA and 1/244 KO DI RN
influenza. a. Northern blot of RNA extracted from cells 48 h after infection
RNA transcribed from genome segment 1 and the 1/244 RNA itself. Lane 1
mRNA. The positions of size markers (nt) are indicated. b. Viral RNAs synthe
primer extension. Samples were taken 48 h after transfection with plasmids
1/244 AUG KO DI RNAs. Lane 1: a 10 nt size ladder; lane 2: RNA made in th
1/244 AUG KO DI RNA. The positions of vRNA and mRNA are indicated. 5S
inoculated intranasally with A/WSN alone (10 LD50, 1000 f.f.u.), A/WSN + 1/
1/244 AUG KO DI virus, A/WSN + inactivated 1/244 DI virus, or saline alone
challenged with a high dose of A/WSN (10,000 LD50) at 3 weeks post-infec
clinical score. In panel C A/WSN + 1/244 DI, 1/244 KO DI only, 1/244 DI on
clinical score of 1. The percentage of surviving mice is shown in parenthesRNA is replicated by the infectious helper virus and acts as
a template for both replication and transcription from a
fully functional RNP complex equivalent to those found
with the genomic RNA segments [23].
Expression of a putative protein by 1/244 DI RNA is not
required for interference in vitro or protection against
disease in vivo
The mRNA transcribed from 1/244 DI RNA contains
the translation start codon of the PB2 open reading
frame 1 (ORF-1). This has the potential to encode a pro-
tein comprising the first 41 amino acid residues of PB2
fused to 21 amino acid residues translated from a differ-
ent reading frame generated as a result of the deletion,
making a protein of 62 residues in total (Fig. 1b). This
putative protein contains the entire PB1-binding domain
of residues 1–35 [33] and the mitochondrial localisation
domain of residues 1–22 [52]. We investigated whether
the putative protein was required for the previously re-
ported protection from infection by 1/244 DI RNA byA by Northern blot and primer extension and protection of mice from
with 1/244 DI virus and helper virus to detect positive-sense influenza
: total RNA; lane 2: non-polyadenylated RNA; lane 3 polyadenylated
sised by 1/244 DI RNA and 1/244 AUG KO DI RNA and detected by
expressing Seg 1-GFP, PB1, PB2, PA and NP proteins and 1/244 and
e presence of 1/244 DI RNA; lane 3: RNA made in the presence of
ribosomal RNA was measured as a loading control. c. Mice were
244 AUG KO DI virus, A/WSN + 1/244 DI virus, A/WSN + inactivated
. Each DI virus comprised 1 μg protein. d. Surviving mice were
tion to determine their immune status. Panels C and D show the mean
ly, and mock are all hidden under A/WSN + 1/244 AUG KO DI with a
is
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ation codons. The PB2 ORF has three possible AUG
start codons and to be sure there could be no translation
initiation all three possible start codons were mutated
(to AUC). The new RNA is referred to as 1/244 AUG
KO DI RNA.
RNAs were harvested 48 h after transfection of 293T
cells with plasmid encoding either the 1/244 DI RNA or
the 1/244 AUG KO DI RNA together with plasmids ex-
pressing the PB2, PB1, PA and NP proteins. Primer ex-
tension analysis, using a mixture of primers to detect
both positive- and negative-sense RNAs simultaneously
(Table 1), showed that 1/244 and 1/244 AUG KO syn-
thesised both types of RNA with the predicted sizes,
confirming that both genomes acted as templates for
RNA synthesis in transfected cells. Densitometric ana-
lysis followed by normalisation against the 5S rRNA
loading control showed that the levels of mRNA synthe-
sized by 1/244 and 1/244 AUG KO DI RNAs were simi-
lar (mRNA/5S ratios of 0.87 and 0.9, respectively)
confirming that transcription was unaffected by the mu-
tations in the 1/244 AUG KO DI RNA (Fig. 2b).
In our experience all stocks of influenza virus contain
some level of a complex population of DI viruses, which
makes examination of the activity of any individual
transfected DI RNA in a cell culture infection model
technically impossible. In such experiments it is neces-
sary to use a high level of infectious virus which results
in a prominent signal from the naturally occurring DI
RNAs that obscures the signal from the transfected plas-
mid expressing 1/244 DI RNA (unpublished data). We
have therefore used an established in vitro RNP reconsti-
tution approach [53–55] to examine the ability of DI
RNAs to interfere with the expression of green fluores-
cent protein (GFP) from a Seg 1-GFP construct. Here
the coding region of GFP is inserted in-frame into a de-
leted influenza segment 1 RNA (Fig. 1a). This system
also distinguishes effects of DI RNA on RNA synthesis
from any effect on RNA packaging as plasmids encoding
key structural proteins (HA, NA, M1 and M2) are not
included [56]. The interfering ability of 1/244 and 1/244
AUG KO RNAs were determined by transfecting 293T
cells with the relevant plasmids and plasmids expressing
Seg 1-GFP and PB1, PB2, PA and NP proteins. 1/244
and 1/244 AUG KO RNAs both strongly inhibited fluor-
escence in a dose-dependent manner (Fig. 3a) with over
90% inhibition at the dose of 0.5 μg for both 1/244 or 1/
244 AUG KO plasmids (Fig. 3b).
To determine whether the in vitro interference is also
reflected in an infection model, we compared the abilities
of 1/244 DI and 1/244 AUG KO DI RNA to protect mice
from disease that normally follows challenge with influenza
A/WSN (H1N1). Virus stocks containing either 1/244 DI
or 1/244 AUG KO DI RNA were produced using reversegenetics as before [51] and mice were infected intranasally
with either A/WSN alone, A/WSN and 1/244 DI virus, or
A/WSN and 1/244 AUG KO DI virus. Additional infected
groups received DI virus which had been UV-irradiated for
8 min to destroy DI protecting activity and to control for
any non-specific effects of the DI virus inoculum [43, 44].
Mice were monitored for clinical disease. Figure 2c shows
that the A/WSN virus-infected control mice all became ser-
iously ill, and had to be culled. In contrast, none of the in-
fected mice also receiving 1/244 DI virus or 1/244 AUG
KO DI virus developed any sign of clinical disease. All mice
treated with A/WSN + 1/244 DI virus or 1/244 KO DI
virus alone were also healthy throughout and these data
points are obscured by those of the A/WSN + 1/244 KO
DI virus. As expected from earlier data mice treated with
UV-inactivated DI virus were not protected [43, 44]. We
have shown previously that animals treated simultaneously
with 1/244 DI virus and infectious virus generate protective
immunity that prevents disease following subsequent chal-
lenge with a high dose of the same virus in the absence of
further treatment with DI virus. Animals treated here with
1/244 AUG KO DI virus were solidly immune to further
challenge with a high dose of A/WSN showing that they
had been infected during the first virus challenge even
though they developed no sign of clinical disease (Fig. 2d).
These data show that interference in vitro or protection
in vivo by 1/244 DI virus does not require expression of a
protein product and is a purely RNA-mediated
phenomenon.
1/244 DI RNA interferes with packaging of segment 1
It was reported previously that the interference mediated
by a DI virus occured at the level of packaging [57], and
we investigated whether this was also the case for DI 1/
244. Human 293T cells were transfected with various
amounts of the 1/244 DI plasmid and a constant amount
of the plasmids needed for the production of infectious A/
WSN virus. These cells were then co-cultivated with
MDCK cells, and at days 1–3 post co-culture the levels of
segments 1, 2 and 7 vRNAs in infected cells and in puri-
fied virus particles were determined. Previously we
showed that influenza vRNAs were only detectable when
all of the virus RNA polymerase components were
present, demonstrating that the vRNAs are generated by
the virus polymerase [46]. 1/244 DI RNA was observed
only in cultures transfected with the 1/244 plasmid, con-
firming that no other segment 1 DI RNA sequences were
generated following transfection (Fig. 4a). We determined
the effect of 1/244 DI RNA on the packaging efficiency of
full-length segment 1 by measuring the ratio of segment 1
to segment 7 in cells and in virions over time in the ab-
sence, or presence of increasing levels, of 1/244 DI RNA.
Packaging of segment 7 in virions is expected to be un-
affected by a segment 1-derived RNA. Therefore, an
Fig. 3 Effect of increasing amounts of DI and full-length genome segment RNAs on expression of GFP from a segment 1 reporter gene construct.
293T cells were transfected with the segment 1-GFP plasmid, plasmids expressing PB1, PB2, PA and NP proteins, and increasing amounts of an add-
itional PolI plasmid expressing a DI RNA (1/244, 1/244 KO, 2/265 or 3/262) or a full-length vRNA (segment 1, 4 or 6). Cells were exam-
ined for fluorescence 2 days after transfection. a. Pairs of cell monolayer images taken by phase-contrast (left) and epifluorescence
microscopy (right). The amount of each plasmid expressing the various RNAs used as putative inhibitors is shown on the left. Control
cells (top) were transfected with an empty vector (1 μg). b. Quantitation of fluorescence in cells generated in the presence of trans-
fected plasmids expressing 1/244 DI, 1/244 KO DI, 3/262 DI, full-length segment 1 and full-length segment 6 RNAs, as indicated in the
key. Columns show the mean of 3 (1/244 RNA, segment 1 and segment 6) or 2 (1/244 KO DI RNA and 3/262) independent experiments, and bars are
standard errors of the mean. c Quantitation of fluorescence in cells generated in the presence of transfected plasmids expressing full-length segment 4
RNA (black columns) and DI 2/265 RNA (grey columns). Columns show the mean of 2 independent experiments, and bars are standard errors of the mean.
Statistical significance determined using a two-tailed Student’s t test; p values for specific comparisons are shown
Meng et al. Virology Journal  (2017) 14:138 Page 8 of 16alteration in the ratio of intracellular versus packaged
RNA segments indicated whether full-length segment 1
was affected by the presence of the DI RNA. Measuring
the ratio of segment 1 to segment 7 also controls for any
overall reduction in production of infectious virus parti-
cles due to the presence of the DI RNA. As the amount of
transfected 1/244 DI plasmid DNA was increased there
was a progressive reduction of segment 1 in cells (Fig. 4a
upper panel) and a corresponding reduction in virus in-
fectivity on each of the days examined (Fig. 4c). This con-
firmed that 1/244 DI RNA-mediated interference was
taking place. The reduction in infectious particle produc-
tion was mirrored by a reduction in virion RNA levels,
with no segment 1, 2 or 7 vRNAs detected in the presence
of 1 μg of 1/244 DI plasmid DNA (Fig 4a, b, lower panels).Quantitation showed that in the presence of 1/244 DI
RNA, the ratio of full-length segment 1 vRNA: segment 7
vRNA was considerably lower in virions than in cell ex-
tracts (Fig. 4d). This established that 1/244 DI RNA acts,
at least in part, by selectively excluding full-length cognate
segment 1 vRNA from progeny virus particles. The seg-
ment 2 vRNA content of virions was not reduced in the
presence of increasing amounts of 1/244 plasmid (Fig. 4b,
d), confirming that inhibition of packaging of segment 1
by 1/244 DI RNA was specific, and did not extend to
other polymerase component-encoding RNA segments.
The origin of the band in the total cellular RNA under-
neath the segment 2 signal is not known, but is likely arise
from a non-specific interaction of the probe with cellular
RNA.
Fig. 4 Effect of DI RNA on the accumulation and encapsidation of viral RNAs. 293T cells were transfected with increasing amounts of the 1/244
DI PolI plasmid (0, 0.1, 0.5 and 1.0 μg) and a constant amount of the plasmids needed for the expression of infectious A/WSN virus. After co-
cultivation with MDCK cells RNA was extracted from cells and from virus particles purified from culture fluids. a. RNA extracted from cell lysates
(top panel) and virus particles from supernatants (lower panel) at 1, 2 and 3 days post co-cultivation was analysed with probes specific for seg-
ment 1 RNA, segment 7 RNA, and 1/244 DI RNA. The sizes of RNA markers are shown on the left and the identity of the RNAs on the right. b. Cell
lysate RNA and virion RNA extracted on day 3 were analysed with probes specific for segment 2 RNA and segment 7 RNA. c. A/WSN infectivity in
cell supernatants measured by microplaque assay. The infectivities on 1 (■), 2 (▲) and 3 (●) days after co-cultivation are shown. Data are the
mean of 2 independent experiments with the bar representing the range. d. The ratios of levels of segment 1 RNA to segment 7 in virions on
days 2 (■) and 3 (●) and of segment 2 RNA to segment 7 in virions on day 3 (▼) were determined by densitometry. These values were compared
with the equivalent ratios determined from transfected cells. The ratios of segment 1 or segment 2 in virions over total cellular RNA were calcu-
lated and normalised to the value determined in the absence of 1/244 DI RNA
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segment 1
To distinguish between the effects of DI RNA on viral
RNA synthesis and RNA packaging, GFP expression from
the Seg 1-GFP construct was determined as described
above. Human 293T cells were transfected with Seg 1-
GFP and plasmids expressing PB1, PB2, PA and NP pro-
teins, and GFP fluorescence determined 2 days post-
transfection. In addition, increasing amounts of a PolI plas-
mid expressing either DI 1/244 or an alternative DI RNA
(2/265 or 3/262, containing 244, 265 and 262 nt from the
3′ end of the cognate vRNAs, respectively: Fig 1a) or a full-
length vRNA not expressing a polymerase component (seg-
ment 4 or 6) were transfected. In control experiments, in-
creasing amounts of a PolI plasmid encoding full-length
vRNA for segment 1 were added to determine whether the
presence of segment 1 sequences in general inhibited GFP
expression. In the absence of the expression plasmidencoding the PB2 protein no GFP expression was detected
confirming the requirement for formation of a functional
vRNP complex (data not shown). Figure 3a shows substan-
tial expression of fluorescence in the absence of any DI
RNA, while increasing levels of 1/244 DI led to significantly
diminished GFP expression. In contrast, inhibition was far
less marked when cells were transfected with plasmids that
synthesised full-length segments 1, 4 or 6 vRNAs. The in-
hibitory effect of 1/244 DI RNA was highly significantly dif-
ferent to that of segment 6 RNA, with 0.1 μg of 1/244 DI
plasmid required to inhibit GFP fluorescence by 70%,
whereas 10-fold more of the segment 6 plasmid was needed
to produce a similar level of inhibition (61–69%) (Fig. 3b).
The presence of 1 μg of segment 4 plasmid DNA reduced
segment 1-derived gene expression by only 25% (Fig. 3c).
Thus 1/244 DI RNA strongly inhibits gene expression from
a segment 1 target RNA. Addition of full-length segment
1 had only a relatively small effect with 1 μg plasmid DNA
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effect of the DI plasmids was due to their unique sequences
and not to a general effect of segment 1 terminal sequences.
Further assays showed that the segment 2- and segment 3-
derived DI RNAs (2/265 and 3/262, respectively) also
strongly inhibited GFP fluorescence from the segment 1-
derived target (Fig. 3a-c), with 1 μg of the 2/265 and 3/262
DI plasmid DNAs reducing expression to 2% and 6% of the
control, respectively.
1/244 DI RNA inhibits positive-sense RNA synthesised from
genome segments 1, 2 and 3 but from not segment 6
Expression of GFP from the Seg 1-GFP PolI plasmid is
dependent on transcription of the negative-sense vRNA
into mRNA. However, vRNA is also template for cRNA,
which in turn acts as template for the production of more
vRNA. Influenza virus mRNA has a 5′-extension of ap-
proximately 12 nt cleaved from host mRNA [10] and is
polyadenylatedso the mRNA and cRNA products are dis-
tinguishable by size. Using Seg 1-GFP plasmid with the
transfection protocol described above, and a primer exten-
sion assay that detects vRNA, mRNA and cRNA, weFig. 5 Analysis of influenza segment 1-directed RNA synthesis by primer extens
6 RNA. 293T cells were transfected with plasmids as described in Fig. 3. Primer e
presence of increasing amounts of plasmid encoding 1/244 DI RNA (panel a), g
from the same RNA preparations were used as an internal control. The primer e
viral RNA from three independent experiments by phosphorimaging analysis is
ised against the relevant 5S rRNA and are expressed as a percentage of the ma
the target plasmid were subtracted from the total as decribed in the text. The e
vRNA (■), mRNA (▲) and cRNA (▼)investigated 1/244 DI RNA mediated interference of RNA
synthesis (Fig. 5). Viral RNAs were all of the predicted
sizes indicating that the templates generated the correct
products. RNA levels were normalised to the 5S loading
control levels before quantitation and the levels of vRNA
were also adjusted to account for basal transcription from
the target plasmids. Basal transcription was calculated as a
percentage of the vRNA:5S RNA ratio in the absence of
both the plasmid pcDNA-PB2 (which encodes a critical
component of the virus polymerase), and of any interfer-
ing RNA (see Fig. 7e, lane 1). This value (0.93%) was sub-
tracted from the vRNA levels. Values of zero indicate that
no vRNA was detected above the basal level.
Quantitation of the primer extension products showed
that mRNA and cRNA levels were considerably more re-
duced than was vRNA in the presence of 0.1 μg to 0.5
μg of 1/244 plasmid DNA (Fig. 5a, b). Addition of 0.1 μg
of 1/244 plasmid DNA reduced mRNA and cRNA levels
to 13% and 10% of the control, respectively, while the
level of vRNA was reduced to only 54% of the control
(vRNA:mRNA p = 0.0052, vRNA:cRNA p = 0.016).
However, 0.5 μg and 1 μg of 1/244 reduced the levels ofion in the presence of influenza 1/244 DI RNA, segment1 RNA, or segment
xtension analysis of viral RNA directed by segment 1-GFP in the absence or
enome segment 1 vRNA (c) or genome segment 6 (e). 5S rRNA detected
xtension products are identified on the left of each panel. Quantitation of
shown in panels (b), (d), and (f). The values of band intensities were normal-
ximum value for each RNA analysed. Basal levels of vRNA generated from
rror bars represent the standard error of the mean of at least 3 replicates.
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while levels of vRNA remained at 14%. Thus 1/244 DI
RNA has a profound effect on all RNAs synthesised
from the segment 1 target, but differentially targets posi-
tive-sense RNAs. To control for the specificity of action
of the inhibiting RNA, either a segment1 (encoding the
intact PB2 gene) or a segment 6 (encoding the NA gene)
plasmid was transfected in the place of the DI RNA
plasmid. Fig. 5c-f show that segment 1 and 6 RNAs were
significantly less effective at inhibiting mRNA, cRNA
and vRNA expression from the segment 1 target than
was 1/244 DI RNA. This is consistent with the lower
level of fluorescence inhibition achieved by the seg-
ments 1 and 6 RNA (Fig. 3a). The reduction in the
level of segment 1-GFP encoded mRNA and the re-
duction in GFP fluorescence (Figs. 3 and 5) were
strongly positively correlated (R2 = 0.90; data not
shown), confirming that fluorescence was a faithful
marker of mRNA synthesis.
To determine if 1/244 DI RNA-mediated inhibition of
RNA synthesis is segment specific, the segment 1 target
(Seg1-GFP) was replaced with a plasmid directing the
synthesis of either full-length segment 2, segment 3 or
segment 6 vRNAs. Fig. 6a-d shows that 1/244 DI RNA
reduced the levels of all three RNAs synthesized by seg-
ment 2 or segment 3, whereas segment 6 mRNAFig. 6 The effect of influenza 1/244 DI RNA on the level of RNA transcribed
transfected with plasmids as described in Fig. 3. Analysis of RNA derived fro
segment 6 in panel (d) in the presence of increasing amounts of 1/244 DI
shown for segment 2 (b) and segment 3 (d) and three independent exper
three experiments. vRNA (■), mRNA (▲) and cRNA (▼)production was unaffected even at the highest amount
of 1/244 DI plasmid transfected (1 μg), cRNA and vRNA
levels were reduced to 12% and 23% of the control value,
respectively. Although inhibition of segment 2-derived
RNAs by 1/244 DI RNA (Fig. 6a, b) more closely resem-
bled that seen for Seg1-GFP (Fig. 5a, b) than for segment
3 or 6 target RNAs (Fig. 6c-f), four-fold more 1/244
plasmid DNA was required to reduce segment 2 mRNA
levels to 13% of the control than was needed for Seg 1-
GFP. The trend of reduction of mRNA, cRNA and
vRNA levels with the segment 3 target in duplicate samples
was similar though slightly less pronounced (Fig. 7c, d).
Overall, the data are consistent with a mechanism whereby
1/244 DI RNA reduces levels of mRNA synthesized from
segments 1, 2 and 3, but not from segment 6.
1/244 DI RNA inhibits synthesis of its own negative-sense
vRNA but not its own positive-sense RNA
In light of the ability of 1/244 DI RNA to differentially
reduce the level of segment 1-encoded RNAs, we inves-
tigated whether the levels of positive- and negative-sense
RNAs synthesised from the 1/244 DI RNA itself were
also affected. RNA was extracted from 293T cells trans-
fected with increasing levels of 1/244 DI RNA, and plas-
mids expressing PB1, PB2, PA and NP proteins, in the
presence or absence of Seg1-GFP DNA (Fig. 7a, c).from influenza genome segments 2, 3 and 6. 293T cells were
m segment 2 is shown in panel (a), segment 3 in panel (c) and
RNA. Quantitation of viral RNA from two independent experiments is
iments for segment 6 (f). The error bars represent the range of data for
Fig. 7 The effect of 1/244 DI RNA on its own levels of transcribed RNA in the presence or absence of seg 1-GFP. Human 293T cells were
transfected with pPolI-244 and expression plasmids as described in Fig. 3. Primer extension analysis of levels of RNA transcribed from 1/244 DI
RNA in the presence (a) or absence (c) of 1.0 μg segment 1-GFP. The faint band indicated by (*) is the extension product from the pcDNA PB2
expression plasmid used in the transfection. b shows the quantitation of viral RNA levels from four independent experiments with the standard
error of the mean, and (d) shows the range for two replicates. vRNA (■), positive-sense RNA (cRNA + mRNA) (▲). The effect of omitting the plasmid expressing
the influenza PB2 protein on virus RNA synthesis is shown in panel (e)
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vRNA, cRNA and mRNA using primer extension, in
these experiments the gel electrophoresis could not dis-
tinguish the positive-sense cRNA and mRNA. However,
Fig. 7a, b show that in the presence of the Seg 1-GFP
target, 1/244 DI positive-sense RNA levels increased in
proportion to the amount of transfected 1/244 DI plas-
mid. Thus these were maximal at the same time as the
Seg 1-GFP mRNA and cRNA levels were at a minimum
as shown in Fig. 5a, b. This shows that 1/244 DI RNA
does not inhibit all influenza polymerase-directed tran-
scription. However, the level of 1/244 DI-specific vRNA
was reproducibly maximal with 0.1 μg 1/244 plasmid
DNA, but decreased to 12% of the maximum value with
0.5 μg plasmid (vRNA: positive-sense RNA p = 0.0002),
and to 4% with 1 μg plasmid (Fig. 7b) demonstrating
that a high concentration of 1/244 DI RNA reduces the
level of its own de novo produced vRNA. When the 1/
244 plasmid DNA was titrated in cells in the absence of
any target RNA the resulting levels of 1/244 positive-
sense RNA and vRNA were similar to those in the pres-
ence of segment 1 target RNA (Fig. 7c, d). The effects of
1/244 DI RNA on RNA synthesis were entirely
dependent on transcription of the target RNA carriedout by the virus polymerase as omission of the expres-
sion plasmid that provides the PB2 protein that forms
part of the virus RNA polymerase, and which is encoded
by segment 1, resulted in no expression of Seg1-GFP
mRNA or cRNA, although low levels of vRNA tran-
scribed directly from the input plasmid DNA were de-
tected as expected (Fig. 7e).
Discussion
Despite many years of investigation, the mechanisms of
the interfering action of DI influenza viruses in vitro and
protection from disease in vivo remain elusive [58–62].
It is commonly held that the small size of the DI RNA
allows it to outcompete the full-length genome, and that
the proportion of virus particles containing DI genomes
simply reflects the relative levels of DI and intact ge-
nomes present within infected cells [63]. A second hy-
pothesis is that DI RNA has a comparative advantage
over full-length genomes for a limiting viral factor (such
as the NP protein) or a host factor [64]. However, there
is little experimental evidence to support either of these
hypotheses in regard to DI genomes in general, or to in-
fluenza DI genomes in particular. A more recent third
hypothesis suggests that the influenza DI RNA interferes
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[57]. There have also been suggestions that different in-
fluenza DI sequences have different biological properties
[41]. Here we investigated the mechanism of action of
the cloned influenza A segment 1-derived 1/244 DI virus
and demonstrated that its DI RNA inhibits infectious in-
fluenza A viruses at the level of packaging of virion RNA
and by specific inhibition of virus RNA synthesis.
We have demonstrated that the activity of 1/244 DI is
solely an RNA-based phenomenon. DI mRNAs that re-
tain the AUG initiation codon of the major open reading
frame have the potential to be translated into truncated
peptides, as already demonstrated for some other seg-
ment 1-derived DI RNAs [65], and analogous short poly-
peptides containing the PA protein binding domain of
the PB1 protein strongly inhibited influenza A RNA
polymerase activity [66, 67]. A truncated form of the
PB2 protein was also shown to be a potent inducer of
interferon that could inhibit influenza A replication [68].
Mutation of the AUG initiation codon for PB2 and two
further downstream in-frame AUG codons that could
direct synthesis of short polypeptides from the PB2 ORF
in the 1/244 DI RNA segment (Fig. 1b) generated a 1/
244 AUG knock-out DI RNA that was replicated and
packaged and indistinguishable in action from that of
the parental 1/244 DI RNA. Virus containing the 1/244
AUG KO DI RNA protected mice from an influenza
challenge to a similar extent to 1/244 DI virus. DI 1/244
KO RNA synthesised vRNA and mRNA to similar levels,
and inhibited GFP expression from segment 1 to a simi-
lar extent as did 1/244 DI RNA.
Analysis of RNA present in virus particles suggests
that 1/244 DI RNA is preferentially packaged over its
cognate full-length segment 1 RNA into nascent virions
(Fig. 4). Thus, in infected cells 1/244 DI RNA is found
as a virion RNP and acts in a segment-specific manner
similar to that reported for the segment 1-derived 317
DI RNA in a non-cloned virus population [57], and for
cloned 317 DI virus [69]. This is consistent with current
models suggesting that influenza genome segments form
arrays consisting of a single copy of each segment
(whether full-length or DI) and that these arrays act as
single structures which become packaged into new virus
particles [70–73]. These data indicate that competition
for packaging with the cognate full-length genomic RNA
is likely to be a common feature of all influenza DI
RNAs.
It was not possible to use in vitro infection to study
interference by the 1/244 DI genome due to the natural
occurrence of DI RNAs in all infectious influenza prepa-
rations, their activity masking any signal from the DI
RNA synthesized from the transfected plasmid. We
therefore used the well-characterised RNP reconstitution
assay to investigate viral RNA synthesis in the absenceof virion production. While initial transcription events
in this system require PolI driven plasmid transcription,
for most of the 48 h time course of the assay virus pro-
teins are synthesised from the newly synthesised virus
RNAs as they are in a natural infection. Analysis of the
effect of the 1/244 DI genome on mRNA synthesis from
a segment 1 target genome RNA, measured directly or
by monitoring expression of a reporter gene, showed
that 1/244 DI RNA interfered with the synthesis of seg-
ment 1 (Fig. 3). The considerably weaker level of inhib-
ition mediated by full-length segments 1, 4 and 6
confirmed that this effect was 1/244 DI RNA-specific.
Inhibition seen with increasing levels of plasmid DNA
expressing genome segments 1, 4 and 6 may be due to
high levels of these RNAs competing for a limiting fac-
tor such as the virus polymerase complex.
The synthesis of positive- (mRNA and cRNA) and
negative-sense (vRNA) RNAs are distinct processes
[20, 21]. Data presented here show that 1/244 DI
RNA produces positive- and negative-sense RNAs
with the predicted sizes and differentially affects the
steady state levels of the RNA products expressed by
various targets. Increasing amounts of transfected 1/
244 DI plasmid dramatically reduced full-length seg-
ment 1-derived positive-sense mRNA and cRNA
levels but four-fold more plasmid DNA was required
to reduce negative-sense vRNA to similar levels (Fig.
5a, b). This contrasts with an earlier report that the
segment 1-derived 317 DI virus did not inhibit RNA
synthesis, though in that study the DI RNA was not
molecularly cloned and has a different sequence to 1/
244 [57]. Surprisingly, 1/244 DI RNA also strongly
inhibited mRNA synthesis from segments 2 and 3
(Fig. 6) suggesting that genome segments 1–3 (encod-
ing components of the virus RNA polymerase) share
a common feature(s) that permits the inhibitory ac-
tion of segment 1 DI RNAs. This was reciprocated as
DI RNAs 2/265 and 3/262 inhibited GFP expression
from the segment 1 target (Fig. 3). This is the first
demonstration that an influenza DI RNA can dramat-
ically affect gene expression from a genome segment
other than that from which it arose. At levels of 1/
244 DI RNA which strongly reduced the level of tar-
get mRNA from segment 1, its own positive-sense
RNA levels were maximal (Fig. 7a, b). Thus, 1/244 DI
RNA can transcribe from itself while suppressing syn-
thesis from the target segment 1 RNA.
These data provide the first description of a novel
mechanism for preferential production of flu DI RNA
compared to RNA production from the cognate genome
segment. As the amount of transfected 1/244 DNA was
increased there was a proportionate decrease in the
mRNA, cRNA and vRNA synthesised by the segment 1
target RNA (Fig. 5) whereas, with transfection of low
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the 1/244 DI RNA template increased (Fig. 7). However,
the situation is complicated as higher levels of 1/244 DI
plasmid caused a reduction in the amount of DI vRNA.
This reduction is not yet understood. The observed de-
cline in DI vRNA levels suggests there could be an im-
balance in the synthesis of the three DI RNAs in which
vRNA, which is templated by and therefore dependent
on DI cRNA, loses out. This would appear to be a self-
limiting phenomenon not previously described for DI
virus systems.
The reduction of mRNA levels by 1/244 DI RNA, indi-
cated by the expression of GFP, was not observed when
full-length segments 4 or 6 were used as the target, indi-
cating that 1/244 DI RNA does not interfere with all
genome segments and appears to act selectively on the
synthesis of positive-sense RNA from segments 1, 2 and
3. Others have shown that segments 1, 2 and 3 direct
the synthesis of considerably lower levels of mRNA rela-
tive to vRNA compared with other genome segments,
and it has been suggested that segments 1–3 mRNAs
are produced by primary transcription rather than tran-
scription from newly synthesised vRNA [74, 75]. Thus
transcription from the three largest genome segments
and the other segments appears to differ. Data presented
here suggest that DI RNAs derived from segments 1, 2
or 3 suppress transcription from segments 1, 2 and 3 by
affecting this transcription process. However, they do
not have this effect on segment 6 which, in common
with segments 4, 5, 7 and 8, is transcribed primarily
from newly synthesised genomes. Large quantities of
short RNA molecules, referred to as svRNA or leRNA,
are produced during influenza infection [76, 77], and
may play a role in the switch from transcription to repli-
cation [76]. If correct, this raises the possibility that a DI
RNA may serve as the template for the production of
svRNAs, which in turn modulate the production of the
replication products vRNA, cRNA, and mRNA. The
mechanism(s) by which these different synthetic pro-
cesses in segments 1, 2 and 3 are affected is not known,
and it will be of interest to investigate if this is common
to all influenza DI RNAs or is a property only of certain
specific DI RNAs. That is, the huge number of DI RNAs
that can be produced during an influenza infection may
vary quantitatively and/or qualitatively in the interference
they exert.
The ability of influenza DI RNAs to supplant their cog-
nate genome segment during the packaging process ex-
plains their amplification in virus preparations. However,
data presented here also indicate that the widely held view
that interference results solely from the ability of the DI
RNA to be replicated faster than the longer, cognate full-
length RNA, while possibly a contributory factor, need not
always be the only mechanism involved. Rather, the 1/244DI RNA specifically targets the synthesis of full-length
genome segments 1, 2 and 3. Further DI RNAs derived
from segments 2 and 3 also inhibit RNA synthesis from
full-length segment 1. Inhibition primarily affects seg-
ments 1–3 as RNA synthesis directed by segment 6 is
inhibited to a significantly lesser degree. Taken together,
the data suggest that interference depends upon a direct
association between each DI RNA and segment 1. Since
all virion and DI RNAs form RNP complexes with NP
protein, we suggest that specific interactions reside in the
DI RNA itself through an element, which might be a se-
quence, a motif comprising non-contiguous sequences, or
a structural motif. This may be analogous to the associ-
ation of genome segments through direct RNA: RNA in-
teractions that have been described as a component of
virus packaging [72, 78–83].
Conclusions
The data presented here suggest there may be previously
unknown interactions between full-length RNAs 1, 2 or
3 and their cognate DI RNAs, possibly mediated through
yet to be identified recognition elements. These interac-
tions appear to confer complex yet highly specific effects
on viral transcription, and is therefore likely to be of
evolutionary significance to the survival of the virus.
This would suggest that DI RNAs are not a mere acci-
dent of replication, as frequently proposed, but may have
evolved as a non-heritable means of negatively regulat-
ing virus infection. These findings take us closer to un-
derstanding the evolutionary significance of DI RNAs
and their interactions with infectious virus, and nearer
to understanding the action of antivirals based on DI
RNAs.
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